公开(公告)号：US10238645B2

公开(公告)日：2019-03-26

申请号：US15990590

申请日：2018-05-26

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12 ,  A61K31/4745

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US09642998B2

公开(公告)日：2017-05-09

申请号：US14641089

申请日：2015-03-06

Applicant: MEDICIS PHARMACEUTICAL CORPORATION

Inventor： Michael T. Nordsiek ,  Kodumudi S. Balaji

IPC: A61K31/00 ,  A61M35/00 ,  B05B11/00 ,  A61K9/00 ,  A61K9/06 ,  A61K31/4745 ,  A61K47/10

CPC classification number: A61M35/003 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/06 ,  A61K31/4745 ,  A61K47/10 ,  B05B11/0037 ,  B05B11/0038 ,  B05B11/00416 ,  B05B11/00446 ,  B05B11/3001 ,  B05B11/3042 ,  B05B11/3047

Abstract: The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).

公开(公告)号：US20230020422A1

公开(公告)日：2023-01-19

申请号：US17177116

申请日：2021-02-16

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K31/4745 ,  A61K31/44 ,  A61K9/00 ,  A61K47/10 ,  A61K47/12

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US20200276182A1

公开(公告)日：2020-09-03

申请号：US16268230

申请日：2019-02-05

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Sharon F. Levy ,  James Hurn-Joung Lee ,  James H. Kulp ,  Kodumudi S. Balaji ,  Tze-Chiang Meng ,  Jason J. Wu ,  Valyn S. Bahm ,  Robert Babilon

IPC: A61K31/4745 ,  A61K31/47 ,  A61K31/437 ,  A61K47/10 ,  A61K9/06 ,  A61K9/00 ,  A61K9/70 ,  A61K47/12 ,  A61K47/14

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.

公开(公告)号：US20190216796A1

公开(公告)日：2019-07-18

申请号：US16364023

申请日：2019-03-25

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K31/4745 ,  A61K47/10 ,  A61K47/12 ,  A61K31/44 ,  A61K9/00

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US20180271854A1

公开(公告)日：2018-09-27

申请号：US15990590

申请日：2018-05-26

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K31/4745 ,  A61K47/12 ,  A61K47/10 ,  A61K9/00 ,  A61K31/44 ,  A61K9/06

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US20140187575A1

公开(公告)日：2014-07-03

申请号：US14091965

申请日：2013-11-27

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K31/4745

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Abstract translation: 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-2-酮的药物制剂和方法， 4-胺，即咪喹莫特，以现在由美国食品和药物管理局（FDA）批准的5％咪喹莫特乳膏市售的治疗时间短于治疗的生殖器/肛周疣， 被公开和描述。 更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（“FDA”）。

公开(公告)号：US11850245B2

公开(公告)日：2023-12-26

申请号：US17177116

申请日：2021-02-16

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12 ,  A61K31/4745

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12 ,  A61K9/06

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US10918635B2

公开(公告)日：2021-02-16

申请号：US16364023

申请日：2019-03-25

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12 ,  A61K31/4745

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

公开(公告)号：US09078889B2

公开(公告)日：2015-07-14

申请号：US14091965

申请日：2013-11-27

Applicant: Medicis Pharmaceutical Corporation

Inventor： Michael T. Nordsiek ,  Jefferson J. Gregory

IPC: A01N43/42 ,  A61K31/44 ,  A61K31/4745

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

Abstract translation: 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-2-酮的药物制剂和方法， 4-胺，即咪喹莫特，以现在由美国食品和药物管理局（FDA）批准的5％咪喹莫特乳膏市售的治疗时间短于治疗的生殖器/肛周疣， 被公开和描述。 更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（“FDA”）。